



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
612 EAST LAMAR BLVD, SUITE 400
ARLINGTON, TEXAS 76011-4125

June 23, 2008

Eastern Idaho Health Services, Inc.
dba Eastern Idaho Regional Medical Center
ATTN: James Neeley, M.D.
Radiation Safety Officer
P.O. Box 2077
Idaho Falls, ID 83403-2077

SUBJECT: LICENSE AMENDMENT AND NOTIFICATION PER 10 CFR 35.14(a)(1)

Please find enclosed Amendment No. 25 to NRC License No. 11-27346-01, **acknowledging your notification and authorizing Dr. James Harris as an Authorized User for 10 CFR 35.392 and §35.394 uses. Dr. James Harris is currently an authorized user under 10 CFR 35.290 and thus meets the training and experience requirements for 10 CFR 35.392 and §35.394. In addition, the submitted attestation documents the required case work as required by 10 CFR 35.392(c)(2)(vi) and 10 CFR 35.394(c)(2)(vi).**

The NRC medical list server has been set up. The list server will send automatic e-mail notifications of medical-related generic communications, Federal Register Notices, and NMSS/FSME newsletters as they are published. Anyone may subscribe/unsubscribe to the new medical list server by sending an e-mail to medical-gc@nrc.gov with "Subscribe" or "Unsubscribe" in the subject line.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review the enclosed document carefully and be sure that you understand all conditions. If you have any questions regarding your NRC license, please contact me at 817-276-6552

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC in writing of any change in mailing address.
3. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:
 - a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);

- b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;
 - c. The licensee's mailing address changes;
 - d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or
 - e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.
4. Request and obtain a license amendment before you:
- a. Change Radiation Safety Officers;
 - b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;
 - c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or
 - d. Change the name or ownership of your organization.

In addition, please note that NRC Form 313 requires the applicant, by signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant. Since the NRC also accepts a letter requesting amendment of an NRC license, the signatory for such a request should also be the licensee or certifying official rather than a consultant.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the NRC Enforcement Policy. The NRC Enforcement Policy is available on the following internet address: <http://www.nrc.gov/reading-rm/doc-collections/enforcement/>.

The NRC no longer publishes the NRC Rules and Regulations loose leaf supplements. However, an electronic version of the NRC's regulations is available on the NRC Web site at www.nrc.gov. Additional information regarding medical uses of radioactive materials may be obtained on the NRC Web site at: <http://www.nrc.gov/materials/miau/med-use-toolkit.html>. This site also provides the updated Training and Experience NRC Form 313A series of forms and guidance, as well as information on the revised regulations for naturally-occurring and accelerator-produced radioactive materials (NARM).

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at <http://www.nrc.gov/reading-rm/adams.html>.

Thank you for your cooperation.

Sincerely,

A handwritten signature in black ink that reads "Rachel S. Browder". The signature is written in a cursive style with a large, sweeping flourish at the end.

Rachel S. Browder, Health Physicist
Nuclear Materials Safety Branch B

Docket: 030-32290
License: 11-27346-01
Control: 471757


Enclosure: As stated

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Eastern Idaho Health Services, Inc. dba Eastern Idaho Regional Medical Center</p> <p>2. P.O. Box 2077 Idaho Falls, Idaho 83403-2077</p>	<p>In accordance with letter dated February 15, 2008</p> <p>3. License number 11-27346-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date May 31, 2013</p> <p>5. Docket No. 030-32290 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Gadolinium-153</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (Medi Physics, Inc. Model 6711, Best Medical International, Inc. Model 2300 series, IsoStar Texas, Inc. Model IS-125 series, North American Scientific Model MED 3631, BEBIG GmbH Model I25.S06, International Brachytherapy Model 125IL, Implant Sciences Corporation Model 3500, Draximage, Inc. Model LS-1, Mills Biopharmaceuticals, Inc. Models I-125SL and I-125SH, IsoAid LLC Model IAI-125A, Isotron Isotopentechnik Model 130.002, Isotope Products Laboratories Model 67-800 series, 3M Model 6500 series, or AEA Technology Model CDC.T1 J series)</p> <p>E. Sealed sources (North American Scientific, Inc. Model 3601 or Du Pont Merck Pharmaceuticals Company Model NES-8412)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 400 millicuries</p> <p>D. 400 millicuries</p> <p>E. 300 millicuries per housing, total possession 1,200 millicuries</p>
---	--	---



UNITED STATES NUCLEAR REGULATORY COMMISSION

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
11-27346-01

Docket or Reference Number
030-32290

Amendment No. 25

6. Byproduct, source, and/or special nuclear material
- F. Iodine-125 permitted by 10 CFR 35.1000
7. Chemical and/or physical form
- F. Liquid as Proxima Therapeutics, Inc. Iotrex™
8. Maximum amount that licensee may possess at any one time under this license
- F. 5 curies

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any use permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. For use in the ADAC Laboratories Models 2146-3536 and 2146-3440 transmission line source housing.
- F. For brachytherapy use in the Proxima Therapeutics' GliaSite® Radiotherapy system permitted by 10 CFR 35.1000.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:
- A. 3100 Channing Way, Idaho Falls, Idaho.
11. The Radiation Safety Officer for this license is James Neeley, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use:

Authorized Users

Material and Use

James Neeley, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
James P. Edlin, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
John D. Chambers, Jr., M.D.	35.200; Gadolinium-153 for patient attenuation correction
John J. Strobel, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
James Harris, M.D.	35.100; 35.200; oral administration of sodium iodide I-131; Gadolinium-153 for patient attenuation correction

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
11-27346-01

Docket or Reference Number
030-32290

Amendment No. 25

Authorized Users

Material and Use

James Schmutz, M.D.

35.100; 35.200; Gadolinium-153 for patient attenuation correction

Michael C. Biddulph, M.D.

35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction

Michael T. Callaghan, M.D.

35.300; 35.400; Gadolinium-153 for patient attenuation correction

Calvin McAllister, M.D.

35.300; 35.400; Gadolinium-153 for patient attenuation correction; 35.1000 only Iodine-125 Gliasite RTS System

David R. Warden III, M.D.

35.100; 35.200; Gadolinium-153 for patient attenuation correction

Douglas U. Blank, M.D.

35.200; Gadolinium-153 for patient attenuation correction

Steven D. Smith, M.D.

35.100; 35.200; oral administration of sodium iodide I-131; Gadolinium-153 for patient attenuation correction

Peter Lead Vance, M.D.

35.100; 35.200; Gadolinium-153 for patient attenuation correction

Thomas J. Maley, M.D.

35.200; Gadolinium-153 for patient attenuation correction

Steven J. Todd, M.D.

35.300; 35.400

Allan Wray, M.D.


35.100; 35.200; 35.300

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
11-27346-01Docket or Reference Number
030-32290

Amendment No. 25

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated December 26, 2002 (ML030300013)
 - B. Letter dated May 27, 2003 (ML031681396)
 - C. Letter dated May 12, 2005 (ML051710487)
 - D. Letter dated June 7, 2005 (ML051710487)
 - E. Letter dated August 18, 2005 (ML052310584)
 - F. Letter dated March 22, 2006 (ML061000533)
 - G. Facsimile dated April 6, 2006 (ML061000533)
 - H. Letter dated September 26, 2006 (ML070250093)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 23, 2008

By: _____

Rachel S. Browder
Rachel S. Browder, Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011